Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages January 6, 2026 8:00 AM EST
Company Participants
William Roberts – Senior VP of Corporate Communications & Investor Relations
Neal Walker – Co-Founder, CEO & Chairman
Hugh M. Davis – President, COO & Director
Jesse Hall – Chief Medical Officer
Roland Kolbeck – Chief Scientific Officer
Conference Call Participants
Biren Amin – Piper Sandler & Co., Research Division
Raghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division
Jiale Song – Jefferies LLC, Research Division
Charles Ndiaye – Stifel, Nicolaus & Company, Incorporated, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Pujan Patel – Leerink Partners LLC, Research Division
Presentation
Operator
Good day and thank you for standing by. Welcome to the Aclaris ATI-052 Clinical Trial Update Conference Call. [Operator Instructions]
Please note that today’s conference is being recorded. I will now hand the conference over to your speaker host, Will Roberts, Head of Communications. Please go ahead.
William Roberts
Senior VP of Corporate Communications & Investor Relations
Thank you, Olivia, and good morning, everyone, and welcome to the Aclaris Therapeutics conference call to review the positive interim results from our ATI-052 Phase Ia single and multiple ascending dose trial. The press release on these clinical results was issued this morning and can be found in the Press Releases sub-page of the Investor Relations section of our corporate website, aclaristx.com.
Please note that we’ve provided the slides as part of this discussion, and they’re now available in the webcast window as a downloadable PDF document. We’ll reference the slide numbers throughout. As mentioned, the Q&A session will follow the prepared remarks.
Before we begin, I’d like to remind you that today’s webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
